the phenotypic changes necessary to down-regulate tumor cells. We have initiated a tumor data base including patients with all grades of ovanan cancer as well as normal ovanies. The data base is intended to document the genes associated with signal transduction, cell-cycle, or cell-surface control mechanisms that may be insulted (mutated) or whose expression may be modified as a result of the transformation process. Such information may aid the selection of appropriate biologic modifiers for gene therapy. The data base is presently being developed by examining the sequence and expression status of known oncogenes and suppressor genes by isolating mRNA from fresh frozen specimens and using polymerase chain reaction (PCR) to examine the products derived from cDNA synthesized from mRNA. We have looked at the expression of p53 and p21 and sequenced p53 to determine mutations. Our overall findings corroborate other investigations in that approxrimately 50% of high-stage tumors have p53 mutations and underexpress the p21 gene. We have also begun to evaluate cell-cycle control genes because of their obvious potential in contributing to the growth of tumors that may or may not Once retinoblastoma protein is phosphorylated, it releases the transcription factor E2F, which is required for progression from G' to the S phase of the cell cycle.6 There also exists a series of suppressors of cell division, which includes p21, pI6, p15, and p107.24 Among these suppressors, p16 has been documented as frequently mutated in many cell lines, presumably producing a dysfunctional p16 protein product, which cannot inhibit the CDK4 and CDK6 kinase reaction. 7 9 More recently, in a senies of primary tumors, it has been established that relatively few specimens had documentable mutations in p16. '1-2 In this report, we examine the expression and mutational status of the p16 gene in ovarian carcinoma with regard to both type and stage of disease. The products were separated on a 2% agarose gel, and the radioactivity of each band was determined using a Phospho Imager (Molecular Dynamics).
MATERIALS AND METHODS

Direct cDNA Sequencing
To prepare the template DNA for the sequencing reaction, we performed PCR with the amplification primers as described earlier. The p16 cDNA was sequenced from codon 40 to the terminal amino acid, covering from the middle of exon 1 through the end of exon 3. Amplified cDNA samples were purified using Wizard PCR Preps DNA purification system (Promega). The sequencing reaction was carried out using a PRISM Ready Reaction DveDeoxy Terminator Cycle Sequencing Kit (Applied Biosysterns). To remove excess DyeDeoxy, spin columns were used (Princeton Separation). An applied Biosystems Model 373A DNA Sequencing System was used for direct cDNA sequence determination.
Western Blotting
A protein lysate was prepared fronm 0.5 g of frozen tissue pulverized under liquid nitrogen. We added to the tissue 0.5 mL of 2 X sodium dodecylsulfate (SDS) sample buffer (62.5 mnol/L Tris-HCl, pH 6.8, 4% SDS, ).01% glycerol, 0.05o% 2-p-mercaptoethanol, and 0.05% bromiophenol blue) containing 10 prmol/L phenylarsine oxide, 2 mnmol/L sodium orthovanadate, 1.3 mmol/L ethyleneglycol-bis-(P-aminoethylether)-N, N. N', N'-tetra-acetic acid, and 100 p. mol/L trifluoperazine. The sanriple was placed in a boiling water bath for 5 nirutes and thereafter was centrifuged at I10,1)00 rpm for 10 minutes. The supernatant at 50 ptg protein/lane Was used for electrophoresis on a 13% SDS polvacrvlamide gel.
Proteins were transferred electrophoreticaily to PVDF niembranes (Bio-Rad) for 220 hours at 3Al V. Membranes were 96 J Soc Gynecol Invest Vol. 4 CDK4/6 complex, shich controls cell passage through the G1 phase of the cell cycle by phosphorylation of the retinoblastoma protein (Figure 6 ). In this manner, p16 could act as a tumor suppressor gene. Conflicting results have been reported concerning the frequency of p16 mutations. It has been reported that p16 homozygous deletions were found frequentlyv in cell lines derived from a wide variety of human tumors, including lung, breast, brain, skin, bladder, kidnev, and ovary, as well as in leukemia aInd nielanoma.-" However, it has also been reported that the frequency of intragenic p16 nsutations was quite low in primary tumor samples of lung, brain, bladder, kidney, ovarn, liver, colon, and head and neck-(l With respect to ovarian tumnors, Kamb et 
